SANDOZ SIMVASTATIN TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

SIMVASTATIN

可用日期:

SANDOZ CANADA INCORPORATED

ATC代码:

C10AA01

INN（国际名称）:

SIMVASTATIN

剂量:

80MG

药物剂型:

TABLET

组成:

SIMVASTATIN 80MG

给药途径:

ORAL

每包单位数:

30/100

处方类型:

Prescription

治疗领域:

HMG-COA REDUCTASE INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0122415005; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2021-04-13

产品特点

_ _
_Sandoz Simvastatin _
_Page 1 of 50_
_ _
PRODUCT MONOGRAPH
PR
SANDOZ SIMVASTATIN
SIMVASTATIN TABLETS, USP
5 MG, 10 MG, 20 MG, 40 MG AND 80 MG
LIPID METABOLISM REGULATOR
Sandoz Canada Inc.
Date of Revision:
145 Jules-Léger
January 4, 2018
Boucherville, Quebec
J4B 7K8
Submission Control No.: 211930
_ _
_Sandoz Simvastatin _
_Page 2 of 50_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
...............................................................................24
PHARMACEUTICAL INFORMATION
..........................................................................24
CLINICAL TRIALS
..........................................................................................................25
DETAILED PHARMACOLOGY
.............